NDAORALCAPSULE
Approved
May 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ADVIL COLD AND SINUS (ibuprofen, pseudoephedrine hydrochloride) by GSK is cyclooxygenase inhibitors [moa]. Approved for these symptoms associated with the common cold, flu: headache fever sinus pressure nasal congestion minor body aches, pains. First approved in 2002.
Drug data last refreshed 21h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADVIL COLD AND SINUS is an oral combination product containing ibuprofen (a nonsteroidal anti-inflammatory drug) and pseudoephedrine hydrochloride (a decongestant) approved in 2002. It treats symptoms associated with the common cold and flu, including headache, fever, sinus pressure, nasal congestion, and minor body aches. The ibuprofen component works by inhibiting cyclooxygenase enzymes to reduce inflammation and pain, while pseudoephedrine acts as a nasal decongestant.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating potential team consolidation and shift toward value-based positioning.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Worked on ADVIL COLD AND SINUS at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.